ABPRO, Hires Former Merck Vice President and Others... "Accelerating Clinical Trials for COVID-19 Treatment"

[Asia Economy Reporter Hyunseok Yoo] ABPROBIO's U.S. subsidiary, ABPRO Corporation, announced on the 30th that it has appointed external advisory board members to accelerate the development of a treatment for the novel coronavirus infection (COVID-19).

The newly appointed external advisory board members are world-renowned authorities in the fields of infectious diseases and viruses: Dr. George Hanna, former Vice President of Merck; Dr. Daniel Kuritzkes, professor at Harvard University; and Dr. Steven Schnitman, professor at Yale School of Medicine, totaling three members.

Dr. George Hanna, former Vice President of Merck, served as the chief officer in charge of infectious diseases and global clinical development therapeutics during his tenure, possessing extensive experience necessary for clinical drug development and academic research.

He also served as the head of the global antiviral project team at Abbott and as the clinical research head of the virology department at Bristol-Myers Squibb. He earned a Bachelor of Biology from Harvard University and a medical degree from Baylor College of Medicine.

Dr. Daniel Kuritzkes is an authority in infectious diseases who has published numerous papers on antiretroviral therapy and drug resistance in AIDS virus patients. He is currently a professor at Harvard Medical School and head of the infectious diseases department at Boston Brigham and Women's Hospital.

Dr. Kuritzkes has actively engaged in AIDS-related external activities and currently serves as the editor-in-chief of the Journal of Infectious Diseases. He holds bachelor's and master's degrees from Yale University and a medical doctorate from Harvard Medical School.

Dr. Steven Schnitman previously worked as a head at Bristol-Myers Squibb. He has experience obtaining final approvals from regulatory agencies worldwide for more than ten new drugs and drug supplements.

Dr. Schnitman is currently a professor at Yale School of Medicine and a physician at West Haven VA Medical Center, advising on clinical development plans and handling approvals and commercialization tasks with regulatory agencies worldwide. He earned bachelor's degrees in biology and economics from New York University and a medical degree from New York University School of Medicine.

Ian Chen, CEO of ABPRO Corporation, said, "At this critical time ahead of the global Phase 2 clinical trial of ABP300, we have appointed external advisory board members who are authorities in viruses and infectious diseases and have clinical development experience with global regulatory agencies. We expect the upcoming global Phase 2 clinical trial to gain momentum."

He added, "In particular, Dr. Schnitman has extensive experience in clinical planning and responding to regulatory agencies worldwide for final approvals, so ABP300 is expected to accelerate final approval and commercialization from the U.S. FDA and regulatory agencies around the world."

This content was produced with the assistance of AI translation services.